Report: Personalized Medicine: Technologies and the Global Market TOC

Chapter-1: SUMMARY 2

SUMMARY TABLE GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 4
SUMMARY FIGURE GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY TECHNOLOGY, 2007-2014 ($ MILLIONS) 5

Chapter-2: MARKET OVERVIEW 15

MARKET OVERVIEW 6
FIGURE 1 PERSONALIZED MEDICINE VS CONVENTIONAL TREATMENTS 7
FIGURE 2 FOCUS OF PERSONALIZED MEDICINE 8
CHANGING TRENDS: FROM BLOCKBUSTER MODEL TO PERSONALIZED MODEL 9
FIGURE 3 PERSONALIZED MEDICINE VS BLOCKBUSTER DRUGS 10
MAJOR MARKET DRIVERS 11
ACCURACY AND PREVENTIVE DIAGNOSIS 11
COST - EFFECTIVE IN LONG RUN 11
RECUPERATIVE BENEFITS 11
MORE EFFECTIVE THAN CONVENTIONAL TREATMENTS 11
MARKET RESTRAINTS 11
RELUCTANCE AMONG PHARMACEUTICAL COMPANIES 12
LEGAL ISSUES DUE TO INTELLECTUAL PROPERTY RIGHTS 12
LACK OF INSURANCE COVERAGE 12
FIGURE 4 MAJOR MARKET TRENDS IN PERSONALIZED MEDICINE 13
STAKEHOLDERS' OPPORTUNITIES 13
FIGURE 5 PARTICIPATION OF STAKEHOLDERS 14
TABLE 1 GLOBAL MARKET FOR STAKEHOLDERS, THROUGH 2014 ($ MILLIONS) 15
DEFINING THE OVERALL PERSONALIZED MEDICINE MARKET 15
FIGURE 6 MARKET STRUCTURE FOR PERSONALIZED MEDICINE 15
DEFINING THE PERSONALIZED MEDICINE TECHNOLOGY MARKET 16
FIGURE 7 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY TECHNOLOGY, 2007-2014 ($ MILLIONS) 16
DEFINING THE PERSONALIZED MEDICINE PRODUCTS AND SERVICES MARKET 17
TABLE 2 GLOBAL PERSONALIZED MEDICINE MARKET BY PRODUCTS AND SERVICES, THROUGH 2014 ($ MILLIONS) 17
DEFINING THE PERSONALIZED MEDICINE APPLICATIONS MARKET 18
TABLE 3 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 18
DEFINING THE PERSONALIZED MEDICINE MARKET BY GEOGRAPHY 18
FIGURE 8 GLOBAL MARKETS FOR PERSONALIZED MEDICINE, 2009 (%) 19
PATENT ANALYSIS 19
FIGURE 9 NUMBERS OF PATENTS ISSUED, JAN. 2004 - APR. 2009 20

Chapter-3: GLOBAL PERSONALIZED MEDICINE MARKET BY TECHNOLOGY 40

GLOBAL PERSONALIZED MEDICINE MARKET BY TECHNOLOGY 21
FIGURE 10 POSITIONING VARIOUS TECHNOLOGIES IN THE MARKET FOR PERSONALIZED MEDICINE 22
ANALYSIS OF PATENTS BY TECHNOLOGY 23
FIGURE 11 SHARE OF PATENTS BY TECHNOLOGY (%) 23
GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE 24
TABLE 4 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES, THROUGH 2014 ($ MILLIONS) 24
TABLE 5 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 25
MARKET DRIVERS 25
Increased Health Awareness and Preventive Diagnosis to Boost the Demand for Pharmacogenomics 25
Increased Revenue Opportunities for Diagnostic and Drug Companies 25
Enhanced Treatment and Better Drug Efficacy Rate 25
MARKET RESTRAINTS 26
Intellectual Property Rights Problem 26
Legal Issues within Nations 26
PHARMACOGENOMIC SERVICES MARKET 26
TABLE 6 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014 ($ MILLIONS) 27
TABLE 7 GLOBAL PHARMACOGENOMICS SERVICES MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 27
Global Market for SNP Genotyping 27
Cost Effective Sequencing Boosts Demand 28
Oligopoly Market Restrains Entry of New Companies 28
Global Market for SNP Genotyping Services 28
TABLE 8 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY DIAGNOSIS METHODS, THROUGH 2014 ($ MILLIONS) 29
TABLE 9 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014 ($ MILLIONS) 29
Global Market for SNP Genotyping Products 29
TABLE 10 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 ($ MILLIONS) 30
Major Companies and Products 30
TABLE 11 MAJOR PRODUCTS IN SNP GENOTYPING 30
Global Market for Pharmacogenomic Drug Discovery and Delivery 30
TABLE 12 GLOBAL DRUG DISCOVERY AND DELIVERY MARKET IN PHARMACOGENOMICS, THROUGH 2014 ($ MILLIONS) 31
Market for SSR - Based Diagnosis 31
TABLE 13 GLOBAL SSR BASED DIAGNOSIS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 32
Market for VNTRs - Based Diagnosis 32
TABLE 14 GLOBAL VNTR BASED DIAGNOSIS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 32
Global Market for Pharmacogenomic Therapy 33
TABLE 15 GLOBAL PHARMACOGENOMIC THERAPY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 33
Global Market for Other Pharmacogenomic Services 33
TOP COMPANIES 33
TABLE 16 MAJOR COMPANIES AND RESPECTIVE PRODUCTS IN PHARMACOGENOMIC SERVICES 34
PHARMACOGENOMIC PRODUCTS MARKET 34
TABLE 17 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 ($ MILLIONS) 34
TABLE 18 GLOBAL PHARMACOGENOMICS PRODUCTS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 35
Markets for Pharmacogenomic Drugs 35
TABLE 19 GLOBAL PHARMACOGENOMICS DRUGS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 35
Markets for Equipment in Pharmacogenomics 36
TABLE 20 GLOBAL PHARMACOGENOMICS EQUIPMENT MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 36
MAJOR TECHNIQUES 36
TABLE 21 GLOBAL MARKET FOR MAJOR PHARMACOGENOMIC TECHNIQUES IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 37
GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE 37
TABLE 22 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES, THROUGH 2014 ($ MILLIONS) 38
TABLE 23 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 38
MARKET DRIVERS 38
Superior Diagnostic Results with Protein Studies 38
High Revenue Generation Attracts More Market Players 39
MARKET RESTRAINTS 39
Continuous Change in Protein Formation Makes it a Costly Treatment 39
TOP COMPANIES 39
TABLE 24 MAJOR PRODUCTS IN PHARMACOPROTEOMICS 39
MARKET FOR PHARMACOPROTEOMICS SERVICES 40
TABLE 25 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014 ($ MILLIONS) 40
TABLE 26 GLOBAL PHARAMCOPROTEOMICS SERVICES MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 41
PHARMACOPROTEOMIC PRODUCTS 41
TABLE 27 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 ($ MILLIONS) 41
TABLE 28 GLOBAL PHARAMCOPROTEOMICS PRODUCTS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 42
TABLE 29 GLOBAL PHARAMCOPROTEOMICS DRUGS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 42
MAJOR TECHNOLOGIES 43
TABLE 30 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY MAJOR TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 43
GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE 43
TABLE 31 GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 44
TABLE 32 GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 44
MARKET DRIVERS 45
Highly Untapped Market 45
Multiple Treatments with One Stem Cell 45
Government Appreciation in the U.S. for Embryonic Stem Cell Research 45
MARKET RESTRAINTS 45
Time Consuming Treatment 45
Side Effects 46
TOP COMPANIES 46
TABLE 33 MAIN COMPANIES AND PRODUCTS IN STEM CELL THERAPY 46
TABLE 34 RECENT PRODUCTS IN STEM CELL THERAPY 46
ADULT STEM CELL THERAPY 47
TABLE 35 GLOBAL ADULT STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 47
Market Drivers 47
Enhanced Treatment for Spinal Cord Injury and Diseases such as Cancer 47
Federal Funding in the U.S. for Adult Stem Cell Therapy 48
Market Restraints 48
Stem Cell Therapy Requires Frequent Treatment 48
EMBRYONIC STEM CELL THERAPY 48
Market Drivers 49
Enhanced Curative Potential Will Attract More Customers 49
Sufficient Knowledge on many Ranges of Stem Cells 49
Market Restraints 49
Religious and Political Issues 49
OTHER TECHNIQUES 49
GLOBAL POINT OF CARE MARKET IN PERSONALIZED MEDICINE 50
TABLE 36 GLOBAL POINT OF CARE MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 50
MARKET DRIVERS 51
Fast, Easy, and Exact Personalized Care 51
Developed Technology Paves the Way for a Developed Market 51
MARKET RESTRAINTS 51
Time - Consuming Realization of Insurance Policies 51
TOP COMPANIES AND THEIR PRODUCTS 51
TABLE 37 TOP COMPANIES AND THEIR PRODUCTS IN POINT OF CARE 51
TABLE 37 (CONTINUED) 52
TABLE 38 NEW TECHNOLOGIES IN POINT OF CARE 52
GLOBAL METABOLOMICS MARKET IN PERSONALIZED MEDICINE 52
TABLE 39 GLOBAL METABOLOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 53
MARKET DRIVERS 53
Enhanced R&D in Drug Discovery Process 53
Competitive Advantage and Less Regulatory Hurdles in Final Drug Delivery 53
MARKET RESTRAINTS 54
Adopted by Fewer Companies 54
TOP COMPANIES 54
TABLE 40 MAJOR COMPANIES AND THEIR PRODUCTS 54
GLOBAL PHARMACOGENETICS MARKET IN PERSONALIZED MEDICINE 54
TABLE 41 GLOBAL PHARMACOGENETICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 55
MARKET DRIVERS 55
Preventive and Curative Treatments Use Pharmacogenetic Technique 55
Enhanced Drugs for Diseases such as Cancer/Cardiovascular Problems 55
MARKET RESTRAINTS 56
High Cost 56
TOP COMPANIES 56
TABLE 42 MAIN PRODUCTS IN PHARMACOGENETICS 56
GLOBAL PHARMACOKINETICS MARKET IN PERSONALIZED MEDICINE 56
TABLE 43 GLOBAL PHARMACOKINETICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 57
MARKET DRIVERS 57
Better Evaluation of the Body' s Response to the Drug 57
Quantitative Results Make it User Friendly for Patients 57
Untapped Market Means Potential Growth for Companies 58
MARKET RESTRAINTS 58
Assumptions of Mathematical Models Can Give Unwanted Results 58
Costly Treatment Hampers Market Growth 58
TOP COMPANIES 58
TABLE 44 MAIN PRODUCTS IN PHARMACOKINETICS 59
GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE 59
TABLE 45 GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS)
TABLE 45 GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) (contd) 59

Chapter-4: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY SERVICES 10

TABLE 46 GLOBAL PERSONALIZED MEDICINE MARKET BY SERVICES, THROUGH 2014 ($ MILLIONS) 61
TABLE 47 GLOBAL PERSONALIZED MEDICINE SERVICES MARKET, THROUGH 2014 ($ MILLIONS) 62
GLOBAL MARKET FOR DRUG DEVELOPMENT/DRUG DELIVERY SERVICE 62
TABLE 48 GLOBAL DRUG DEVELOPMENT AND DELIVERY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 62
MARKET DRIVERS 63
Shift of Trend from Blockbuster Drugs to Tailored Drugs 63
Higher Efficacy of Drugs with Personalized Medicine 63
MARKET RESTRAINTS 63
Expensive Drugs In Comparison To Blockbuster Drugs 63
TOP COMPANIES 63
GLOBAL MARKET FOR DIAGNOSIS 63
TABLE 49 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC SERVICES MARKET, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 64
TABLE 50 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC SERVICES MARKET, THROUGH 2014 ($ MILLIONS) 65
PHARMACOGENOMICS BASED DIAGNOSIS 65
TABLE 51 GLOBAL PHARMACOGENOMIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014 ($ MILLIONS) 66
Market Drivers 66
Individual Gene Tests are Increasing Revenues for Diagnostic Players 66
Market Restraints 66
Rapidly Evolving Technology is Not Aligned to Fixed Regulatory System 66
PHARMACOPROTEOMICS BASED DIAGNOSIS 66
TABLE 52 GLOBAL PHARMACOPROTEOMIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014 ($ MILLIONS) 67
Market Drivers 67
In - Depth Research Provides a Lot of Information for Diagnosis 67
Market Restraints 67
Costly Treatment Due to Requirement of Continuous Monitoring of Changing Protein Formation 67
PHARMACOGENETICS BASED DIAGNOSIS 68
TABLE 53 GLOBAL PHARMACOGENETIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014 ($ MILLIONS) 68
GLOBAL MARKET FOR MONITORING AND THERAPY SERVICES 68
MONITORING SERVICES 68
TABLE 54 GLOBAL PERSONALIZED MEDICINE MONITORING SERVICES MARKET, THROUGH 2014 ($ MILLIONS) 69
THERAPEAUTIC SERVICES 69
TABLE 55 GLOBAL PERSONALIZED MEDICINE THERAPEUTIC SERVICES MARKET, THROUGH 2014 ($ MILLIONS) 69
GLOBAL MARKET FOR OTHER SERVICES 69
TABLE 56 GLOBAL OTHER SERVICES MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 70

Chapter-5: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY PRODUCTS 15

TABLE 57 GLOBAL PERSONALIZED MEDICINE MARKET BY PRODUCTS, THROUGH 2014 ($ MILLIONS) 71
TABLE 58 GLOBAL PERSONALIZED MEDICINE PRODUCTS MARKET, THROUGH 2014 ($ MILLIONS) 72
GLOBAL PERSONALIZED MEDICINE MARKET FOR DIAGNOSTICS EQUIPMENT 72
TABLE 59 GLOBAL MARKET FOR DIAGNOSTIC EQUIPMENT IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 72
MARKET DRIVERS 73
Increased Demand for Genetic and Proteomic Tests 73
MARKET RESTRAINTS 73
Fast Changing Technology 73
TABLE 60 GLOBAL MARKET FOR MONITORING AND THERAPEUTIC EQUIPMENT IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 73
MARKET DRIVERS 74
Improved Technology Along with Low - Cost Monitoring and Therapeutic Devices 74
GLOBAL PERSONALIZED MEDICINE MARKET FOR BIOINFORMATICS PRODUCTS 74
TABLE 61 GLOBAL MARKET FOR BIOINFORMATICS IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 74
MARKET DRIVERS 75
Bioinformatics Reduces Cost of Drug Development 75
MARKET RESTRAINTS 75
High Initial Investment Hinders Small and Medium Sized Companies 75
GLOBAL PERSONALIZED MEDICINE MARKET FOR DRUGS 75
TABLE 62 GLOBAL MARKET FORECAST FOR DRUGS IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 ($ MILLIONS) 76
TABLE 63 GLOBAL MARKET FORECAST FOR DRUGS IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 76
DRUG STAGES 76
FIGURE 12 PRODUCT LIFE CYCLE FOR PERSONALIZED MEDICINE PRODUCTS 77
GLEEVEC 78
TABLE 64 GLOBAL MARKET FORECAST FOR GLEEVAC IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 78
Market Drivers 78
Higher Efficacy of Gleevec Gives it a Large Consumer Base 78
Gleevec as a Pill Makes it Easy to Consume 79
Assistance for Reimbursement from Insurance Companies 79
Market Restraints 79
High Drug Cost is Affecting Market Growth 79
Inherent Side Effects of Gleevec 79
HERCEPTIN 79
TABLE 65 GLOBAL MARKET FORECAST FOR HERCEPTIN IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 80
Market Drivers 80
Enhanced Treatment with Reduced Risk of Reoccurrence of Breast Cancer 80
Market Restraints 80
Tailor Made Herceptin Still Carries Inherent Side Effects 80
ZIAGEN 81
TABLE 66 GLOBAL MARKET FORECAST FOR ZIAGEN IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 81
Market Drivers 81
Customizable for Children 81
Market Restraints 82
Treatment with Ziagen Cannot Be Restarted 82
IRESSA AND TARCEVA 82
Iressa 82
Market Drivers 82
" Iressa in Pills Makes it User Friendly 82
Market Restraints 83
" FDA Ban on Iressa Is Keeping it Away from the U.S. Market 83
Tarceva 83
TABLE 67 GLOBAL MARKET FORECAST FOR IRESSA & TARCEVA IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 83
ERBITUX 84
TABLE 68 GLOBOL MARKET FORECAST FOR ERBITUX IN PERSONALIZED MEDICINE THROUGH 2014 ($ MILLIONS) 84
Market Drivers 85
Multiple Cancers Are Treated with Erbitux, which Gives it a Large Patient Base 85
Enhanced Survival Results when Radiotherapy Is Combined with Erbitux 85
OTHERS 85
TABLE 69 GLOBAL MARKET FORECAST FOR OTHER DRUGS IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 85

Chapter-6: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY APPLICATIONS 16

GLOBAL MARKET FOR PERSONALIZED MEDICINE BY APPLICATIONS 86
FIGURE 13 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATION, THROUGH 2014 ($ BILLIONS) 87
PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR DISEASE 87
TABLE 70 GLOBAL MARKET FORECAST FOR TREATMENT OF CARDIOVASCULAR DISEASES, THROUGH 2014 ($ MILLIONS) 88
MARKET DRIVERS 88
Possible Preventive Measure 88
MARKET RESTRAINTS 89
Lack of Proactive Approach for Early Diagnosis 89
PERSONALIZED MEDICINE MARKET FOR BREAST CANCER 89
TABLE 71 GLOBAL MARKET FORECAST FOR BREAST CANCER TREATMENT THROUGH 2014 ($ MILLIONS) 90
MARKET DRIVERS 90
Fewer Side Effects with Personalized Medicine 90
MARKET RESTRAINTS 90
Resistance to Adopting New Methods of Treatment 90
RECENT DEVELOPMENTS 90
TABLE 72 RECENT DEVELOPMENTS IN TREATMENT OF BREAST CANCER 91
PERSONALIZED MEDICINE MARKET FOR LEUKEMIA 91
TABLE 73 GLOBAL MARKET FORECAST FOR LEUKEMIA TRETAMENT THROUGH 2014 ($ MILLIONS) 92
MARKET DRIVERS 92
Huge Market Potential for Leukemia 92
MARKET RESTRAINTS 92
Lack of Awareness that Surgery Is the Only Way to Treat Leukemia 92
PERSONALIZED MEDICINE MARKET FOR LUNG CANCER 92
TABLE 74 GLOBAL MARKET FORECAST FOR LUNG CANCER TREATMENT, THROUGH 2014 ($ MILLIONS) 93
MARKET DRIVERS 93
Higher Efficiency Than Conventional Lung Cancer Treatment 93
Availability of Drugs in the Form of Pills Makes Treatment User Friendly 93
MARKET RESTRAINTS 94
Lack of FDA Approval for Certain Personalized Drugs 94
RECENT DEVELOPMENTS 94
PERSONALIZED MEDICINE MARKET FOR TREATING HIV/AIDS 94
TABLE 75 GLOBAL MARKET FORECAST FOR AIDS TREATMENT THROUGH 2014 ($ MILLIONS) 95
MARKET DRIVERS 95
Personalized Medicine Improves Life Expectancy of a Patient 95
Easy Reimbursement for Aids Patients from NGOs/Government Organizations 95
MARKET RESTRAINTS 95
Lack of Awareness Among Patients 95
PERSONALIZED MEDICINE MARKET FOR NEUROLOGICAL DISORDERS 96
TABLE 76 GLOBAL MARKET FORECAST FOR TREATING NEUROLOGICAL DISORDERS, THROUGH 2014 ($ MILLIONS) 96
MARKET DRIVERS 96
Enhanced Treatment 96
MARKET RESTRAINTS 97
Apprehensive to Try Out New Medications 97
PERSONALIZED MEDICINE MARKET FOR DIABETES 97
TABLE 77 GLOBAL MARKET FORECAST FOR TREATMENT OF DIABETES, THROUGH 2014 ($ MILLIONS) 97
MARKET DRIVERS 98
Early Diagnosis Can Help Prevent Diabetes 98
MARKET RESTRAINTS 98
Casual Approach towards Diabetes 98
RECENT DEVELOPMENTS 98
TABLE 78 RECENT DEVELOPMENTS IN TREATING DIABETES 98
PERSONALIZED MEDICINE MARKET FOR ASTHMA 99
TABLE 79 GLOBAL MARKET FORECAST FOR TREATING ASTHMA, THROUGH 2014 ($ MILLIONS) 99
MARKET DRIVERS 99
Every Asthma Case Is Distinct, Needs Custom - Tailored Treatment 99
Asthma Treatment Needs Regular Monitoring 100
OTHER APPLICATIONS 100
TABLE 80 GLOBAL MARKET FORECAST FOR TREATING OTHER CANCER/TUMOR, THROUGH 2014 ($ MILLIONS) 100
TABLE 81 GLOBAL MARKET FORECAST FOR TREATING OTHER DISEASES, THROUGH 2014 ($ MILLIONS) 101

Chapter-7: GLOBAL PERSONALIZED MARKET BY GEOGRAPHY 16

ABBOTT 118
OVERVIEW 118
TABLE 97 PRODUCT PORTFOLIO OF ABBOTT 118
TABLE 97 (CONTINUED) 119
STRATEGY 119
AFFYMETRIX 120
OVERVIEW 120
TABLE 98 PRODUCT PORTFOLIO OF AFFYMETRIX (MICROARRAYS) 120
TABLE 98 (CONTINUED) 121
TABLE 98 (CONTINUED) 122
TABLE 99 PRODUCT PORTFOLIO OF AFFYMETRIX (REAGENTS & ASSAYS) 122
TABLE 99 (CONTINUED) 123
STRATEGY 123
AGENDIA BV 123
OVERVIEW 124
TABLE 100 PRODUCT PORTFOLIO OF AGENDIA BV 124
STRATEGY 124
ASURAGEN 124
OVERVIEW 124
TABLE 101 PRODUCT PORTFOLIO OF ASURAGEN 125
STRATEGY 125
BAYER HEALTHCARE 126
TABLE 102 PRODUCT PORTFOLIO OF BAYER HEALTHCARE 126
STRATEGY 126
BIOGEN (IDEC) 127
OVERVIEW 127
TABLE 103 PRODUCT PORTFOLIO OF BIOGEN (IDEC) 127
STRATEGY 127
BRISTOL - MYERS SQUIBB 128
OVERVIEW 128
TABLE 104 PRODUCT PORTFOLIO OF BRISTOL - MYERS SQUIBB 128
STRATEGY 128
CELERA DIAGNOSTICS 129
OVERVIEW 129
TABLE 105 PRODUCT PORTFOLIO OF CELERA DIAGNOSTICS 129
TABLE 106 NEW PRODUCT DEVELOPMENT OF CELERA DIAGNOSTICS 130
STRATEGY 130
CEPHEID 130
OVERVIEW 130
TABLE 107 PRODUCT PORTFOLIO OF CEPHEID 131
TABLE 107 (CONTINUED) 132
TABLE 107 (CONTINUED) 133
STRATEGY 133
CLINICAL DATA 133
OVERVIEW 134
TABLE 108 PRODUCT PORTFOLIO OF CLINICAL DATA 134
TABLE 108 (CONTINUED) 135
STRATEGY 135
CURAGEN CORP. 135
OVERVIEW 136
TABLE 109 PRODUCT PORTFOLIO OF CURAGEN CORP. 136
STRATEGY 136
DAKO DENMARK A/S 136
OVERVIEW 137
TABLE 110 PRODUCT PORTFOLIO OF DAKO DENMARK A/S 137
TABLE 110 (CONTINUED) 138
STRATEGY 138
DECODE GENETICS 138
OVERVIEW 138
TABLE 111 PRODUCT PORTFOLIO OF DECODE GENETICS 139
TABLE 112 NEW PRODUCT DEVELOPMENT OF DECODE GENETICS 140
STRATEGY 140
DNA DIRECT, INC. 141
OVERVIEW 141
TABLE 113 PRODUCT PORTFOLIO OF DNA DIRECT, INC 141
STRATEGY 142
DXS LTD. 142
OVERVIEW 142
TABLE 114 PRODUCT PORTFOLIO OF DXS LIMITED 143
STRATEGY 143
EXACT SCIENCES CORP. 144
OVERVIEW 144
TABLE 115 PRODUCT PORTFOLIO OF EXACT SCIENCES CORP. 144
STRATEGY 145
EXAGEN DIAGNOSTICS 145
OVERVIEW 145
TABLE 116 PRODUCT PORTFOLIO OF EXAGEN DIAGNOSTICS 145
GENE LOGIC (AN OCIMUM BIOSOLUTIONS COMPANY) 146
OVERVIEW 146
TABLE 117 PRODUCT PORTFOLIO OF GENE LOGIC 146
TABLE 117 (CONTINUED) 147
STRATEGY 148
GENELEX CORP 148
OVERVIEW 148
TABLE 118 PRODUCT PORTFOLIO OF GENELEX CORP 148
TABLE 118 (CONTINUED) 149
TABLE 118 (CONTINUED) 150
STRATEGY 150
GENENTECH, INC. 150
OVERVIEW 151
TABLE 119 PRODUCT PORTFOLIO OF GENENTECH, INC. 151
TABLE 119 (CONTINUED) 152
STRATEGY 152
GENOMIC HEALTH, INC. 152
OVERVIEW 152
TABLE 120 PRODUCT PORTFOLIO OF GENOMIC HEALTH INC 153
STRATEGY 153
GEN - PROBE 153
OVERVIEW 153
TABLE 121 PRODUCT PORTFOLIO OF GEN - PROBE 154
TABLE 121 (CONTINUED) 155
TABLE 121 (CONTINUED) 156
TABLE 122 NEW PRODUCT DEVELOPMENT OF GEN - PROBE 157
STRATEGY 157
GENTA 157
OVERVIEW 157
TABLE 123 PRODUCT PORTFOLIO OF GENTA 158
TABLE 124 NEW PRODUCT DEVELOPMENT OF GENTA 158
STRATEGY 158
GLAXOSMITHKLINE 159
OVERVIEW 159
TABLE 125 PRODUCT PORTFOLIO OF GLAXOSMITHKLINE 159
STRATEGY 159
ILLUMINA 160
OVERVIEW 160
TABLE 126 PRODUCT PORTFOLIO OF ILLUMINA 160
TABLE 126 (CONTINUED) 161
STRATEGY 161
LUMINEX CORP. 161
OVERVIEW 162
TABLE 127 PRODUCT PORTFOLIO OF LUMINEX CORP. 162
MILLENNIUM 162
OVERVIEW 163
TABLE 128 PRODUCT PORTFOLIO OF MILLENNIUM 163
STRATEGY 163
MONOGRAM BIOSCIENCES 163
OVERVIEW 163
TABLE 129 PRODUCT PORTFOLIO OF MONOGRAM BIOSCIENCES 164
STRATEGY 165
MYRIAD GENETICS, INC. 165
OVERVIEW 165
TABLE 130 PRODUCT PORTFOLIOS OF MYRIAD GENETICS 165
TABLE 130 (CONTINUED) 166
TABLE 130 (CONTINUED) 167
TABLE 131 NEW PRODUCT DEVELOPMENT OF MYRIAD GENETICS 167
STRATEGY 167
NANOGEN 168
OVERVIEW 168
TABLE 132 PRODUCT PORTFOLIO OF NANOGEN 168
TABLE 132 (CONTINUED) 169
STRATEGY 169
NOVARTIS 169
OVERVIEW 170
TABLE 133 PRODUCT PORTFOLIO OF NOVARTIS 170
STRATEGY 170
OSMETECH PLC 171
OVERVIEW 171
TABLE 134 PRODUCT PORTFOLIO OF WYETH 171
STRATEGY 171
PROMEGA 172
OVERVIEW 172
TABLE 135 PRODUCT PORTFOLIO OF PROMEGA 172
TABLE 135 (CONTINUED) 173
TABLE 135 (CONTINUED) 174
STRATEGY 175
QIAGEN 175
OVERVIEW 175
TABLE 136 PRODUCT PORTFOLIO OF QIAGEN 176
TABLE 136 (CONTINUED) 177
STRATEGY 177
ROCHE DIAGNOSTICS 178
OVERVIEW 178
TABLE 137 PRODUCT PORTFOLIO OF ROCHE DIAGNOSTICS 178
TABLE 137 (CONTINUED) 179
STRATEGY 180
SIEMENS HEALTHCARE DIAGNOSTICS 180
OVERVIEW 180
TABLE 138 PRODUCT PORTFOLIO OF SIEMENS HEALTHCARE DIAGNOSTICS 180
TABLE 138 (CONTINUED) 181
STRATEGY 181
TARGET DISCOVERY, INC. 181
OVERVIEW 181
TABLE 139 PRODUCT PORTFOLIO OF TARGET DISCOVERY 182
STRATEGY 182
VENTANA MEDICAL SYSTEMS, INC. 182
OVERVIEW 182
TABLE 140 PRODUCT PORTFOLIO OF VENTANA MEDICALSYSTEMS, INC. 183
STRATEGY 183
WYETH 184
OVERVIEW 184
TABLE 141 PRODUCT PORTFOLIO OF WYETH 184
STRATEGY 184
APPENDIX 185
PATENTS ISSUED IN U.S. 185
TABLE 142 PATENTS ISSUED IN THE UNITED STATES 185
TABLE 142 (CONTINUED) 186
TABLE 142 (CONTINUED) 187
TABLE 142 (CONTINUED) 188
TABLE 142 (CONTINUED) 189
TABLE 142 (CONTINUED) 190
TABLE 142 (CONTINUED) 191
PATENTS ISSUED IN EUROPE 192
TABLE 143 PATENTS ISSUED IN EUROPE 192
PATENTS ISSUED IN JAPAN 193
TABLE 144 PATENTS ISSUED IN JAPAN 193

Personalized Medicine: Technologies and the Global Market

Table of Contents

Chapter-1: SUMMARY 2

Chapter-2: MARKET OVERVIEW 15

Chapter-3: GLOBAL PERSONALIZED MEDICINE MARKET BY TECHNOLOGY 40

Chapter-4: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY SERVICES 10

Chapter-5: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY PRODUCTS 15

Chapter-6: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY APPLICATIONS 16

Chapter-7: GLOBAL PERSONALIZED MARKET BY GEOGRAPHY 16